Case Reports in Oncological Medicine

Case Reports in Oncological Medicine / 2021 / Article

Case Report | Open Access

Volume 2021 |Article ID 8856167 | https://doi.org/10.1155/2021/8856167

Waqas Jehangir, Alexander Karabachev, Jackie Tsao, Christopher J. Anker, Sree Susmitha Garapati, Janusz K. Kikut, Hibba Tul Rehman, "Metastatic Malignant Paraganglioma Presenting as a Neck Mass Treated with Radiolabeled Somatostatin Analog", Case Reports in Oncological Medicine, vol. 2021, Article ID 8856167, 6 pages, 2021. https://doi.org/10.1155/2021/8856167

Metastatic Malignant Paraganglioma Presenting as a Neck Mass Treated with Radiolabeled Somatostatin Analog

Academic Editor: Raffaele Palmirotta
Received09 May 2020
Revised01 Mar 2021
Accepted04 May 2021
Published08 Jun 2021

Abstract

Paragangliomas are rare neuroendocrine tumors that arise from chromaffin-containing tissue. Surgical resection and/or radiation are used for locoregional disease, and reduction of tumor burden with systemic therapy is reserved for metastatic disease. Iobenguane I-131, somatostatin analog (octreotide), and Sunitinib are noncytotoxic options for treatment, while cyclophosphamide, vincristine, and dacarbazine (CVD) and temozolomide are often used as initial chemotherapy options as studies have shown that they offer some tumor response. However, there are no randomized clinical trials demonstrating prolonged survival with the use of chemotherapeutics in metastatic cases. Investigation of alternative therapies that provide survival benefit is thus necessary. We present a case of a 69-year-old female with metastatic malignant paraganglioma presenting as a left parapharyngeal neck mass, which metastasized after surgery, requiring radiation therapy for bony metastasis who was treated with a radioisotope somatostatin analog for disease progression.

1. Introduction

Paragangliomas and pheochromocytomas are rare neuroendocrine tumors that arise from chromaffin-containing tissue. The combined prevalence of these tumors lies roughly between 1 : 6500 and 1 : 2500 with an annual incidence of 500-1600 cases per year in the United States [1]. Sympathetic paragangliomas arise from chromaffin cells along the sympathetic chain in the chest, abdomen, and pelvis, and pheochromocytomas arise from similar cells in the adrenal glands. These two types of tumors are known to synthesize and release catecholamines, which can cause severe hypertension, palpitations, stroke, and possibly death. By contrast, parasympathetic paragangliomas are typically nonfunctional and do not produce symptoms associated with catecholamine hypersecretion. They instead are usually space-occupying lesions derived from parasympathetic nerves in the head, neck, or mediastinum and may cause pain, hoarseness, and dysphagia secondary to a mass effect on surrounding structures [2]. Parasympathetic paragangliomas are often benign but locally invasive. Surgical resection remains the standard therapy as paragangliomas tend to respond poorly to chemotherapy and radiation [3].

Though typically benign, parasympathetic paragangliomas can become malignant and metastasize. Because spread is rare, there is currently no standard treatment for metastatic malignant paragangliomas. Cyclophosphamide, vincristine, and dacarbazine (CVD) are often used as initial chemotherapy as studies have shown that they offer some tumor response [4]. However, there are no randomized clinical trials demonstrating prolonged survival with the use of chemotherapeutics in metastatic cases [5]. Investigation of alternative therapies that provide survival benefit is thus necessary. We present the case of a 69-year-old female with metastatic malignant paraganglioma who was treated with a somatostatin analog for widespread disease refractory to surgery, radiation, and targeted therapy.

2. Case Presentation

A 69-year-old female with no smoking history or family history of paragangliomas or other neuroendocrine tumors initially noted discomfort in her left neck in 2007 which was thought to be related to a cervical disk pathology; however, by March 2010, her symptoms had persisted and then she had laryngitis for about 5 weeks. She was seen by her doctor who could not hear her left carotid, and she was also noted to have a grayish appearance. A left tonsillar lesion was noted, which was felt to be secondary to medial disposition of the tonsil from some extrinsic compression. A mass was noted at the left angle of the jaw in level 2. She was prescribed antibiotics; however, they did not improve her symptoms and vascular surgery was consulted. A CT angiogram of the neck was performed in 2010. Contiguous axial CT images were obtained of the neck using 80 mL of Isovue-370 IV contrast followed by 60 mL of normal saline infused at 6 mL/seconds. A heterogenous attenuation, hypervascular mass appearing to arise from the left retrostyloid parapharyngeal space was most consistent with a paraganglioma, likely globus vagale. Encasement and marked narrowing of the left cervical internal carotid artery were noted (Figure 1).

MRI was performed which further demonstrated a large left cervical mass causing markedly diminished signal in the cervical left internal carotid artery likely representing diminished flow due to compression by the mass. Prior to surgery, she was put on alpha and beta blockade. She underwent embolization as well as excision of the tumor by a combination of transcervical and transoral approaches with lip and mandibular split. Her tumor was encroaching the left jugular foramen with a persistent tumor evident extending up to the jugular foramen at the termination of the procedure, despite intentional sacrifice of the cranial nerves 9, 10, and 12, given their relationship to the tumor. There was a small portion of the residual tumor that could not be resected at the superior portion of the jugular foramen. The pathology showed an extra-adrenal pheochromocytoma (paraganglioma) from the left carotid space, superior to the carotid bifurcation. Immunohistochemical staining was positive for chromogranin, synaptophysin, and S-100 and was faint for glial fibrillary acidic protein (GFAP). It measured positive lymphovascular invasion, the mitotic rate is 1/10 high-power field, and necrosis was present, likely due to embolization. The margins were positive. She was on surveillance after surgery.

Since her surgery, sequential MRI scans of the brain showed a slowly progressive recurrence. Surgery was not recommended due to potential morbidity. In 2015, she underwent stereotactic radiosurgery at a dose of 15 Gy to the left paraganglioma. In 2016, MRI of the neck with and without contrast revealed a mass lesion centered within the left jugular foramen, appearing mildly increased in size with an unchanged mild mass effect upon the adjacent left cerebellar hemisphere. The size was 20 mm in maximal dimension as opposed to 17 mm compared to previous imaging 6 months prior (Figure 2). A CT scan of the chest showed scattered noncalcified pulmonary nodules. The largest was noted to be in the right middle lobe, demonstrating no discernible growth based on the volumetric analysis compared to previous imaging. Her PET/CT revealed FDG uptake in the right middle lobe pulmonary nodule. She was also found to have FDG uptake within bony lesions involving T3, T7, L3, and the T1 transverse process consistent with metastasis. FDG uptake was noted within the biopsy-proven left jugular foramen paraganglioma. She underwent CT-guided FNA of a 6 mm right middle lobe lesion which revealed neoplastic, low-grade tumor, favoring a neuroectodermal tumor, and after discussion in MDC, it was concluded that her paraganglioma disease was likely metastatic to the lung and spine. She underwent stereotactic ablative radiation therapy to the T7 and T3 paraganglioma metastasis to the spine to a dose of 1600 cGy.

In 2017, she had a T4 vertebral body biopsy and kyphoplasty for her back pain secondary to metastasis. In the fall of 2017, she was found to have a compression fracture and underwent T3 vertebroplasty with improvement in pain. Her MRI of the thoracic and lumbar spine showed multiple osseous lesions (Figure 3). It also showed metastatic disease including the stable lung nodule which was biopsied and mild degenerative disc disease. In January 2018, CT of the chest abdomen pelvis showed stable disease (T3 and T7). CT of the neck showed stable disease in the left jugular foramen. In the spring of 2018, she was diagnosed with a T8 compression fracture and underwent T8 vertebroplasty. She was started on monthly denosumab. In the fall of 2018, CT chest showed stable lung nodules and CT abdomen pelvis showed mixed sclerotic and lytic lesions at L1 and L3 with increased compression of the left side of the superior endplate of L3 since the prior CT. MRI showed that the metastatic lesions in the L-spine were slightly larger without any new lesions. Soft tissue mass in the left jugular foramen appears to be stable without any cervical lymphadenopathy; however, there was a concern of C3 metastatic lesion and metastatic lesions in the thoracic spine that also increased in size. She was referred for genetic testing, and the results came back positive for a mutation in SDH-C, c.397C>T (p.Arg133), which is associated with autosomal dominant hereditary paraganglioma-pheochromocytoma syndromes, gastrointestinal stromal tumors, and renal cell carcinoma [6]. This sequence results in a premature translational stop signal in the penultimate exon of the SDHC mRNA at codon 133 which is expected to delete the last 37 amino acids of the SDHC protein. This variant has been reported in several individuals with paragangliomas [710].

Her case was discussed with local and national experts, and it was recommended to get a gallium 68 dotatate PET scan (as MIBG is not helpful after the lesions have been radiated). She underwent a PET/CT GA-68 dotatate scan in the spring of 2019 which revealed multiple scattered metastatic lesions to the spine with subtle increase in size and conspicuity of a few sacral and lumbar lesions (Figure 4). She was started on lutetium 177 dotatate (Lu 177), a radiolabeled somatostatin analog, in April 2019 and received a half dose in the first cycle due to concerns around catecholamine storm. She had borderline elevated 24-hour urine metanephrine and mildly elevated norepinephrine and dopamine level on plasma catecholamine fractionation and was treated with alpha and beta blockade prior to Lu-177 treatment. Other labs performed prior to treatment include a basic metabolic panel which was all within normal limits, liver function tests which were within normal limits, a complete blood count with a hemoglobin of 10.2 gm/dl, normal platelet count of 368 K/cmm, and normal white blood cell count of 4.82 K/cmm. Her folate was elevated at 24 ng/ml. She tolerated the first cycle and received the full second dose in June 2019. A follow-up PET/CT GA-68 dotatate scan in December 2019 showed a modest response to therapy with no new lesions identified while previously these lesions had been progressively getting worse (Figure 5). During the most recent oncology follow-up visit in February 2020, the patient reports some continued fatigue that is beginning to improve.

3. Discussion

Paragangliomas have varied clinical presentations depending on tumor location and size, catecholamine secretory function, and extent of spread [11]. Biochemical testing is encouraged even for patients who do not exhibit symptoms associated with catecholamine hypersecretion. Catecholamines are metabolized into metanephrines (normetanephrine, metanephrine) in chromaffin cells. In tumors, this process occurs independently of catecholamine release. Diagnosis involves 24 h urine collection to assess for the presence of fractionated metanephrine and catecholamines. Several studies have demonstrated that measurement of urinary metanephrines allows for greater diagnostic sensitivity than measurement of serum metanephrines [1]. Histological studies are then performed for definitive diagnosis [12].

A diagnosis of malignant paraganglioma requires the presence of metastasis [1]. Patients with metastatic involvement have an estimated 5-year survival of <50% [5]. Malignant disease is difficult to treat because metastatic paragangliomas are often refractory to chemotherapy and radiation and recurrence is common. A lifelong follow-up is strongly encouraged. Iobenguane I-131, somatostatin analogs (e.g., octreotide), and Sunitinib are targeted options for treatment, while cyclophosphamide, vincristine, and dacarbazine (CVD) and temozolomide are often used as initial chemotherapy options as studies have shown that they offer some tumor response [1318]. Patients with rapid disease progression are usually treated with chemotherapy or temozolomide, while patients with slow to moderate disease progression are treated with radiolabeled therapies. CVD is the recommended option for rapidly progressive metastatic disease, and the specific regimen includes a 21- to 28-day cycle of cyclophosphamide 750 mg/m2 and vincristine 1.4 mg/m2 on day 1 and dacarbazine 600 mg/m2 on day 1 and 2 [4]. For the SDH-B mutant, CVD is the initial treatment choice while metronomic temozolomide is recommended for patients that do not tolerate the alkylating agents. Another established therapy for metastatic paraganglioma is MIBG therapy and is the preferential therapy for slow growing MIBG-positive metastatic disease [19].

The combination of CVD as an initial chemotherapy regimen was shown to improve symptoms for patients as well as have a high response rate with a median survival of 39 months after initiating treatment [4]. However, a study in 2008 by Huang et al. evaluated eighteen patients 22 years after treatment with CVD for malignant paraganglioma. They reported that the overall survival of patients who had a positive response to CVD did not differ from patients whose disease remained stable or even progressed after treatment. An improvement in symptoms was noted when tumor shrinkage occurred concluding that CVD may be an option to manage symptoms in patients and also for patients where tumor shrinkage may make surgical resection an option [4, 5]. Currently, no chemotherapy regimen has been shown to prolong survival for metastatic paraganglioma.

Radionuclide therapy may be an option for symptom palliation and tumor regression or stabilization. The effectiveness of this treatment is largely dependent on whether the tumor takes up MIBG or somatostatin analogs that the beta-emitting isotopes are coupled to. This is evaluated using Iobenguane I-131 scintigraphy for MIBG or PET imaging using gallium-68-labeled somatostatin analogs [20, 21]. Our patient had positive uptake with the PET/CT GA-68 dotatate scan and was therefore started on lutetium 177 dotatate (Lu 177), a radiolabeled somatostatin analog. It is likely that the increased accuracy of the PET/CT GA-68 dotatate scan is due to the SDH-C deficient status of the patient. In addition to paragangliomas, gastrointestinal stromal tumors, and renal cell carcinoma, SDH mutations have been shown to be related to pituitary tumors [610, 22].

Studies have revealed conflicting results for the use of radiolabeled somatostatin analogs for metastatic pheochromocytoma/paraganglioma. Forrer et al. in 2008 showed that radiolabeled somatostatin analog [DOTA-Tyr(3)]-octreotide (DOTATOC) was effective for patients with receptor-positive paraganglioma. They analyzed 28 patients with surgically incurable disease. The treatment was tolerated well, and of these patients, two had partial remissions, five had minor responses and thirteen had stable disease with a mean follow-up of 19 months. From these results, the authors concluded that DOTATOC may be an effective treatment for paraganglioma but is less effective when compared to its response with gastroenteropancreatic neuroendocrine tumors [23].

In 2018, lutetium Lu-177 dotatate (177Lu-dotatate) was approved by the US FDA for the treatment of gastroenteropancreatic neuroendocrine tumors that express somatostatin receptors. This approval did not include paraganglioma/pheochromocytoma. Our case highlights its use in the setting of somatostatin receptor-positive paraganglioma in hopes of appropriate future application of somatostatin analogs for the treatment of malignant paragangliomas. An ongoing trial by NCI is evaluating the role of Lu-177 for inoperable pheochromocytoma and paraganglioma and is expected to be completed in 2023 (NCT03206060).

Data Availability

All data are available in the manuscript, in the references, or in the ClinicalTrials.gov website.

Disclosure

This case was presented at the Northern New England Clinical Oncology Society Annual Meeting on October 19, 2019, in Rockport, Maine.

Conflicts of Interest

No conflicts of interest exist for this work. Authors are physicians and medical students at the University of Vermont Medical Center.

References

  1. H. Chen, R. S. Sippel, M. S. O'Dorisio et al., “The North American Neuroendocrine Tumor Society consensus guideline for the diagnosis and management of neuroendocrine tumors: pheochromocytoma, paraganglioma, and medullary thyroid cancer,” Pancreas, vol. 39, no. 6, pp. 775–783, 2010. View at: Publisher Site | Google Scholar
  2. J. Welander, P. Söderkvist, and O. Gimm, “Genetics and clinical characteristics of hereditary pheochromocytomas and paragangliomas,” Endocr Relat Cancer, vol. 18, no. 6, pp. R253–R276, 2011. View at: Publisher Site | Google Scholar
  3. K. Nomura, H. Kimura, S. Shimizu et al., “Survival of patients with metastatic malignant pheochromocytoma and efficacy of combined cyclophosphamide, vincristine, and dacarbazine chemotherapy,” The Journal of Clinical Endocrinology and Metabolism, vol. 94, no. 8, pp. 2850–2856, 2009. View at: Publisher Site | Google Scholar
  4. S. D. Averbuch, C. S. Steakley, R. C. Young et al., “Malignant pheochromocytoma: effective treatment with a combination of cyclophosphamide, vincristine, and dacarbazine,” Annals of Internal Medicine, vol. 109, no. 4, pp. 267–273, 1988. View at: Publisher Site | Google Scholar
  5. H. Huang, J. Abraham, E. Hung et al., “Treatment of malignant pheochromocytoma/paraganglioma with cyclophosphamide, vincristine, and dacarbazine: recommendation from a 22-year follow-up of 18 patients,” Cancer, vol. 113, no. 8, pp. 2020–2028, 2008. View at: Publisher Site | Google Scholar
  6. C. J. Ricketts, B. Shuch, C. D. Vocke et al., “Succinate dehydrogenase kidney cancer: an aggressive example of the Warburg effect in cancer,” The Journal of urology, vol. 188, no. 6, pp. 2063–2071, 2012. View at: Publisher Site | Google Scholar
  7. J. K. Bickmann, S. Sollfrank, A. Schad et al., “Phenotypic variability and risk of malignancy in SDHC-linked paragangliomas: lessons from three unrelated cases with an identical germline mutation (p.Arg133),” The Journal of Clinical Endocrinology & Metabolism, vol. 99, no. 3, pp. E489–E496, 2014. View at: Publisher Site | Google Scholar
  8. T. Else, M. L. Marvin, J. N. Everett et al., “The clinical phenotype of SDHC-associated hereditary paraganglioma syndrome (PGL3),” The Journal of Clinical Endocrinology & Metabolism, vol. 99, no. 8, pp. E1482–E1486, 2014. View at: Publisher Site | Google Scholar
  9. M. Lefebvre and W. D. Foulkes, “Pheochromocytoma and paraganglioma syndromes: genetics and management update,” Current Oncology, vol. 21, no. 1, 2014. View at: Google Scholar
  10. K. M. Zbuk, A. Patocs, A. Shealy, H. Sylvester, S. Miesfeldt, and C. Eng, “Germline mutations in PTEN and SDHC in a woman with epithelial thyroid cancer and carotid paraganglioma,” Nature clinical practice Oncology, vol. 4, no. 10, pp. 608–612, 2007. View at: Publisher Site | Google Scholar
  11. D. Erickson, Y. C. Kudva, M. J. Ebersold et al., “Benign paragangliomas: clinical presentation and treatment outcomes in 236 patients,” The Journal of Clinical Endocrinology and Metabolism, vol. 86, no. 11, pp. 5210–5216, 2001. View at: Publisher Site | Google Scholar
  12. C. A. Prades, B. Atassi, and H. Nazeer, “Metastatic malignant paraganglioma: A Case report and review of literature,” World journal of oncology, vol. 8, no. 3, pp. 92–95, 2017. View at: Publisher Site | Google Scholar
  13. J. J. Mukherjee, G. A. Kaltsas, N. Islam et al., “Treatment of metastatic carcinoid tumours, phaeochromocytoma, paraganglioma and medullary carcinoma of the thyroid with (131)I-meta-iodobenzylguanidine [(131)I-mIBG],” Clinical Endocrinology, vol. 55, no. 1, pp. 47–60, 2001. View at: Publisher Site | Google Scholar
  14. F. Tenenbaum, M. Schlumberger, J. Lumbroso, and C. Parmentier, “Beneficial effects of octreotide in a patient with a metastatic paraganglioma,” European Journal of Cancer, vol. 32A, p. 737, 1996. View at: Google Scholar
  15. R. Kau and W. Arnold, “Somatostatin receptor scintigraphy and therapy of neuroendocrine (APUD) tumors of the head and neck,” Acta Oto-Laryngologica, vol. 116, no. 2, pp. 345–349, 1996. View at: Publisher Site | Google Scholar
  16. G. M. O'Kane, S. Ezzat, A. M. Joshua et al., “A phase 2 trial of sunitinib in patients with progressive paraganglioma or pheochromocytoma: the SNIPP trial,” British Journal of Cancer, vol. 120, no. 12, pp. 1113–1119, 2019. View at: Publisher Site | Google Scholar
  17. M. Ayala-Ramirez, C. N. Chougnet, M. A. Habra et al., “Treatment with sunitinib for patients with progressive metastatic pheochromocytomas and sympathetic paragangliomas,” The Journal of Clinical Endocrinology and Metabolism, vol. 97, no. 11, pp. 4040–4050, 2012. View at: Publisher Site | Google Scholar
  18. M. Ayala-Ramirez, L. Feng, M. A. Habra et al., “Clinical benefits of systemic chemotherapy for patients with metastatic pheochromocytomas or sympathetic extra-adrenal paragangliomas: insights from the largest single-institutional experience,” Cancer, vol. 118, no. 11, pp. 2804–2812, 2012. View at: Publisher Site | Google Scholar
  19. S. Nölting, M. Ullrich, J. Pietzsch et al., “Current management of pheochromocytoma/paraganglioma: a guide for the practicing clinician in the era of precision medicine,” Cancers, vol. 11, no. 10, p. 1505, 2019. View at: Publisher Site | Google Scholar
  20. E. van der Harst, W. W. de Herder, H. A. Bruining et al., “[(123)I]Metaiodobenzylguanidine and [(111)in]octreotide uptake in benign and malignant pheochromocytomas,” The Journal of Clinical Endocrinology and Metabolism, vol. 86, no. 2, pp. 685–693, 2001. View at: Publisher Site | Google Scholar
  21. I. Buchmann, M. Henze, S. Engelbrecht et al., “Comparison of 68Ga-DOTATOC PET and 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 34, no. 10, pp. 1617–1626, 2007. View at: Publisher Site | Google Scholar
  22. P. Xekouki and C. A. Stratakis, “Succinate dehydrogenase (SDHx) mutations in pituitary tumors: could this be a new role for mitochondrial complex II and/or Krebs cycle defects?” Endocrine-related cancer, vol. 19, no. 6, pp. C33–C40, 2012. View at: Publisher Site | Google Scholar
  23. F. Forrer, I. Riedweg, H. R. Maecke, and J. Mueller-Brand, “Radiolabeled DOTATOC in patients with advanced paraganglioma and pheochromocytoma,” The Quarterly Journal of Nuclear Medicine and Molecular Imaging, vol. 52, no. 4, pp. 334–340, 2008. View at: Google Scholar

Copyright © 2021 Waqas Jehangir et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Related articles

No related content is available yet for this article.
 PDF Download Citation Citation
 Download other formatsMore
 Order printed copiesOrder
Views716
Downloads704
Citations

Related articles

No related content is available yet for this article.

Article of the Year Award: Outstanding research contributions of 2021, as selected by our Chief Editors. Read the winning articles.